<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)†|Supplementary Appendix 2|
|---|---|---|---|
|Initiation of treatment in DMARD-naive patients with moderate-to-high disease activity| | | |
|Methotrexate monotherapy is strongly recommended over:| | | |
|Hydroxychloroquine or sulfasalazine|Very low/low‡|PICO 2a.C1/C2|p. 14–5|
|bDMARD or tsDMARD monotherapy|Very low/moderate|PICO 5a.C1–4/C5§|p. 61–78|